The FDA drug database lists a supplement dated 24 September 2026 to the approved application for lenvatinib mesylate (Lenvima, Eisai). The entry gives the application number, the product and the sponsor, and nothing about what the supplement changed: it may relate to labelling, manufacturing or a new use.
Because the record does not state the content, it does not tell prescribers of any new indication, dose or safety warning. Supplements are a routine part of a product's lifecycle. Where the text is needed, the supplement approval letter and the updated label on the FDA site are the sources to check.
The entry is a US record. Lenvatinib's approval and use in India are separate matters and are not described here, so the status here is unknown from this source.
- Check the current product information for lenvatinib before prescribing; this entry does not say what changed.
- Review blood pressure, proteinuria and thyroid function monitoring as set out in the label.
- Do not assume a new indication or safety warning from this entry.
- Ask your pharmacy or the manufacturer for the updated label if it matters to your patients.
Why it matters
It is a reminder to read the label change, not just the headline of a regulatory entry.
Don't overread it
A supplement listing does not by itself mean a new indication or a safety finding; the record gives no detail on what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free